How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market

Atea Pharmaceuticals (NASDAQ: AVIR) didn't get the outcome it wanted with a phase 2 study of its oral antiviral therapy AT-527. In this Motley Fool Live video recorded on Oct. 20, Motley Fool contributors Keith Speights and Brian Orelli discuss how Atea's clinical flop shakes up the COVID-19 pill market dynamics.

Continue reading

Source Fool.com